Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Finished Goods (2024 - 2025)

ARS Pharmaceuticals (SPRY) has disclosed Finished Goods for 2 consecutive years, with $7.3 million as the latest value for Q1 2025.

  • Quarterly Finished Goods changed N/A to $7.3 million in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $7.3 million through Mar 2025, changed N/A year-over-year, with the annual reading at $5.2 million for FY2024, N/A changed from the prior year.
  • Finished Goods hit $7.3 million in Q1 2025 for ARS Pharmaceuticals, up from $5.2 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $7.3 million in Q1 2025 to a low of $5.2 million in Q4 2024.